Markus Warmuth - 02 Jan 2026 Form 4 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Reporting relationship: President & CEO, Director
Issuer ticker: GLUE
Reported as of: 02 Jan 2026
Net transaction value: -$153,748
SEC form: 4
Accepted by SEC: 05 Jan 2026, 16:04:37 UTC
Prior SEC filing: 06 Jan 2025
Next SEC filing: 09 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Markus Warmuth

Key filing fact

Markus Warmuth filed Form 4 for Monte Rosa Therapeutics, Inc. (GLUE) on 05 Jan 2026.

Key facts

This page summarizes Markus Warmuth's Form 4 filing for Monte Rosa Therapeutics, Inc. (GLUE).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Jan 2026, 16:04.

Change

Previous filing in this sequence was filed on 06 Jan 2025.
Current net transaction value: -$153,748.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001855643 Primary reporting owner

Warmuth Markus

Relationship: President & CEO, Director
Address: MONTE ROSA THERAPEUTICS, INC., 321 HARRISON AVENUE, SUITE 900, BOSTON
Signature: /s/ Markus Warmuth
Signature date: 05 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GLUE transaction

Common Stock

Award

Transaction value
Shares: +90,000
Change %: +17%
Price
Shares after: 634,538
Date: 02 Jan 2026
Ownership: Direct
Footnotes: F1

GLUE transaction

Common Stock

Sale

Transaction value: $153,748
Shares: -10,135
Change %: -1.6%
Price: $15.17
Shares after: 624,403
Date: 05 Jan 2026
Ownership: Direct
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GLUE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +406,000
Change %
Price: $0.000000
Shares after: 406,000
Date: 02 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 406,000
Exercise price: $15.31
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Represents restricted stock units ("RSUs") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 25% of the RSUs shall vest on January 2, 2027, with the remainder vesting in 3 equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Footnote F2

Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.17 to $15.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F4

25% of this option shall vest and become exercisable on January 2, 2027, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.